Top

Published in:

01-12-2011 | Erectile Dysfunction (Thomas Lue, Section Editor)

Treatment of Peyronie’s Disease: 2012 Update

Authors: Ege Can Serefoglu, Wayne J. G. Hellstrom

Published in: Current Urology Reports | Issue 6/2011

Abstract

Peyronie’s disease (PD) is the occurrence of a fibrous inelastic scar of the tunica albuginea of the penis. It is a relatively common disorder among men, with a reported prevalence of 3% to 8%. It is often associated with penile pain, anatomical deformities in the erect state, and difficulty with intromission. Because the exact pathophysiology of PD remains unknown and standards for evaluating or reporting treatment outcomes are unclear, research on effective therapies has been limited. The benefits of nonsurgical treatment options are conflicting and further controlled studies are required before any therapy can be fully recommended. The success of surgery has been well documented; however, surgery is invasive and costly and carries potential side effects. Patients who report stable disease that has been present for longer than 12 months and who experience penile deformity preventing satisfactory sexual intercourse are best suited for surgery. Additionally, failed conservative management and a patient’s preference for definitive correction are important additional indications for surgical treatment.

•• Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, Levine L. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med. 2010;7(7):2359–74. This recent guideline summarizes the treatment options for PD. PubMed

Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88:727–30.PubMedCrossRef

Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–3.PubMedCrossRef

Williams JL, Thomas GG. The natural history of Peyronie’s disease. J Urol. 1970;103(1):75–6.PubMed

•• Hellstrom WJ. Medical management of Peyronie’s disease. J Androl. 2009;30(4):397–405. This is a very important guideline that highlights the medical treatment for PD. PubMedCrossRef

Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie’s disease. J Urol. 2002;68:1075–9.

Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175:2115–8.PubMedCrossRef

Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl. 2000;21(3):347–54.PubMed

Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie’s disease. Int J Impot Res. 1999;11(4):207–12.PubMedCrossRef

10.

Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Biol Med. 1983;9:41–5.

11.

Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-Lcarnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178:1398–403.PubMedCrossRef

12.

Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie’s disease: a nationwide survey. J Sex Med. 2008;5:954–64.PubMedCrossRef

13.

Zarafonetis CJD, Horrax TM. Treatment of Peyronie’s disease with potassium paraaminobenzoate (Potaba). J Urol. 1959;81:770–2.PubMed

14.

Shah PJR, Green NA, Adib RS, Pryor JP. A multicentre double-blind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie’s disease. Prog Reprod Biol Med. 1983;9:61–7.

15.

Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530–6.PubMedCrossRef

16.

Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44:291–5.PubMedCrossRef

17.

Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12:169–75.PubMedCrossRef

18.

Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238–43.PubMedCrossRef

19.

Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91:522–4.PubMedCrossRef

20.

Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie’s disease with tamoxifen. Br J Urol. 1992;70:648–51.PubMedCrossRef

21.

Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162:2003–5.PubMedCrossRef

22.

Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88:63–7.PubMedCrossRef

23.

Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int. 2002;89:895–900.PubMedCrossRef

24.

Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229–44.PubMedCrossRef

25.

Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3:111–5.PubMedCrossRef

26.

•• Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, Eisenberg ML, Lue TF. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Anrol. 2011;13(2):322–5. This is an interesting article providing data regarding the beneficial effect of pentoxifylline in the treatment of PD. CrossRef

27.

Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med. 2010;7(6):2077–85.PubMed

28.

Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med. 2010;7(5):1787–97.PubMedCrossRef

29.

Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2010;106(2):240–8.PubMedCrossRef

30.

Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472–7.PubMedCrossRef

31.

Bodner H, Howard AH, Kaplan JH. Peyronie’s disease: cortisone hyaluronidase-hydrocortisone therapy. J Urol. 1954;400–3.

32.

Winter CC, Khanna R. Peyronie’s disease: results with dermojet injection of dexamethasone. J Urol. 1975;114:898–900.PubMed

33.

Williams G, Green NA. The non-surgical treatment of Peyronie’s disease. Br J Urol. 1980;52:392–5.PubMedCrossRef

34.

Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res. 1982;10:135–40.PubMedCrossRef

35.

Gelbard MK, Linkner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol. 1985;134:280–3.PubMed

36.

Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. Placebo in the treatment of Peyronie’s disease: a double blind study. J Urol. 1993;149:56–8.PubMed

37.

Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo controlled study. J Sex Med. 2008;5:180–7.PubMedCrossRef

38.

Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93:5478–82.PubMedCrossRef

39.

Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151:1522–4.PubMed

40.

Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51:620–6.PubMedCrossRef

41.

Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology. 2007;69:1181–4.PubMedCrossRef

42.

Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease. Urology. 2007;69:950–4.PubMedCrossRef

43.

•• Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y, Fujiwara T, Kamoi K, Miki T. Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med. 2010;7(11):3743–9. This prospective controlled study provides evidence for the beneficial effect of intralesional nicardipine injection treatment. PubMedCrossRef

44.

Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89–94.PubMedCrossRef

45.

Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie’s disease: a pilot study. Br J Urol. 1997;79(1):40–2.PubMedCrossRef

46.

Polat O, Gul O, Ozbey I, Ozdikici M, Bayraktar Y. Peyronie’s disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol. 1997;29(4):465–71.PubMedCrossRef

47.

Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–8.PubMedCrossRef

48.

Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology. 2006;67:1038–42.PubMedCrossRef

49.

Gelbard M, Lindner A, Chvapil M, Kaufman J. Topical betaaminopropionitrile in the treatment of Peyronie’s disease. J Urol. 1983;129(4):746–8.PubMed

50.

Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology. 1983;21(6):584–5.PubMedCrossRef

51.

Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168(6):2483–5.PubMedCrossRef

52.

Fitch WP, Easterling J, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCI, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease—a placebo-controlled pilot study. J Sex Med. 2007;4(2):477–84.PubMedCrossRef

53.

Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie’s disease. J Urol. 2000;163:95–9.PubMedCrossRef

54.

Di Stasi S, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol. 2004;171:1605–8.PubMedCrossRef

55.

Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Vigili G, Storti L, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int. 2003;91(9):825–9.PubMedCrossRef

56.

Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177:972–5.PubMedCrossRef

57.

Skolarikos A, Alargof E, Rigas A, Deliveliotis Ch, Konstantinidis E. Shockwave therapy as first-line treatment for Peyronie’s disease: a prospective study. J Endourol. 2005;19(1):11–4.PubMedCrossRef

58.

Srirangam SJ, Manikandan R, Hussain J, Collins GN, O’Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie’s disease. J Endourol. 2006;20:880–4.PubMedCrossRef

59.

Michel MS, Ptaschnyk T, Musial A, Braun P, Lenz ST, Alken P, et al. Objective and subjective changes in patients with Peyronie’s disease after management with shock wave therapy. J Endourol. 2003;17:41–4.PubMedCrossRef

60.

Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shock wave therapy for Peyronie’s disease does not correct penile deformity. Int J Impot Res. 2004;16:448–51.PubMedCrossRef

61.

Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy in Peyronie’s disease: results of a prospective approach. J Urol. 2004;171:269–99.

62.

Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171:740–5.PubMedCrossRef

63.

•• Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebo- controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56:363–70. This was the first prospective, randomized, controlled trial that brought up ESWL as a treatment option for PD. PubMedCrossRef

64.

Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106(9):1352–6.PubMedCrossRef

65.

Taylor FL, Levine LA. Non-surgical therapy of Peyronie’s disease. Asian J Androl. 2008;10(1):79–87.PubMedCrossRef

66.

Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5:1468–73.PubMedCrossRef

67.

Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase ii prospective study. J Sex Med. 2009;6:559–66.CrossRef

68.

Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178–80.PubMedCrossRef

69.

Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie’s disease. Curr Opin Urol. 2004;6:381–8.CrossRef

70.

Dimitriou R, Levine LA. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie’s Disease. J Urol. 1999;161:1014A.

71.

Levine LA, Lenting E. A surgical algorithm for the treatment of Peyronie’s disease. J Urol. 1997;158:2149–52.PubMedCrossRef

72.

Mulhall JP, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie’s disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med. 2005;2:132–8.PubMedCrossRef

73.

Ralph DJ, Minhas S. The management of Peyronie’s disease. BJU Int. 2004;93:208–15.PubMedCrossRef

74.

• Kadioglu A, Kucukdurmaz F, Sanli O. Current status of the surgical management of Peyronie's disease. Nat Rev Urol. 2011;8(2):95–106. This is a recent review of surgical treatment modalities for PD. PubMedCrossRef

75.

Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol. 1965;93:230–2.PubMed

76.

Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie’s disease. J Urol. 1979;122(5):622–3.PubMed

77.

Savoca G, Scieri F, Pietropaolo F, Garaffa G, Belgrano E. Straightening corporoplasty for Peyronie’s disease: a review of 218 patients with median follow-up of 89 months. Eur Urol. 2004;46:610–4.PubMedCrossRef

78.

Bokarica P, Parazajder J, Mazuran B, Gilja I. Surgical treatment of Peyronie’s disease based on penile length and degree of curvature. Int J Impot Res. 2005;17:170–4.PubMedCrossRef

79.

Licht MR, Lewis RW. Modified Nesbit procedure for the treatment of Peyronie’s disease: a comparative outcome analysis. J Urol. 1997;158:4603.CrossRef

80.

Ralph DJ, al-Akraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J Urol. 1995;154:1362–3.PubMedCrossRef

81.

Rolle L, Tamagnone A, Timpano M, Destefanis P, Fiori C, Ceruti C, et al. The Nesbit operation for penile curvature: an easy and effective technical modification. J Urol. 2005;173:171–3.PubMedCrossRef

82.

Syed AH, Abbasi Z, Hargreave TB. Nesbit procedure for disabling Peyronie’s curvature: a median follow-up of 84 months. Urology. 2003;61:999–1003.PubMedCrossRef

83.

Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol. 1990;143:80–2.PubMed

84.

Essed E, Schroeder F. New surgical technique for Peyronie’s disease. Urology. 1985;25:582–7.PubMedCrossRef

85.

Daitch JA, Angermeier KW, Montague DK. Modified corporoplasty for penile curvature: long-term results and patient satisfaction. J Urol. 1999;162:2006–9.PubMedCrossRef

86.

Rehman J, Benet A, Minsky LS, Melman A. Results of surgical treatment for abnormal penile curvature: Peyronie’s disease and congenital deviation by modified Nesbit plication (tunical shaving and plication). J Urol. 1997;157:1288–91.PubMedCrossRef

87.

Van Der Horst C, Martinez Portillo FJ, Seif C, Alken P, Juenemann KP. Treatment of penile curvature with Essed-Schroder tunical plication: aspects of quality of life from the patients’ perspective. BJU Int. 2004;93:105–8.CrossRef

88.

Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 2006;175:238–41.PubMedCrossRef

89.

Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow-up. J Sex Med. 2008;5:2221–8.PubMedCrossRef

90.

Gholami SS, Lue TF. Correction of penile curvature using the 16‑dot plication technique: a review of 132 patients. J Urol. 2002;167:2066–9.PubMedCrossRef

91.

Dugi DD, Morey AF. Penoscrotal plication as a uniform approach to reconstruction of penile curvature. BJU Int. 2010;105:1440–4.PubMedCrossRef

92.

Kadioglu A, Sanli O, Akman T, Cakan M, Erol B, Mamadov F. Surgical treatment of Peyronie’s disease: a single center experience with 145 patients. Eur Urol. 2008;53:432–9.PubMedCrossRef

93.

Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie’s disease. J Sex Med. 2007;4:1500–8.PubMedCrossRef

94.

Lowsley OS, Boyce WH. Further experiences with an operation for the cure of Peyronie’s disease. J Urol. 1950;63:888–902.PubMed

95.

Gelbard MK, Hayden B. Expanding contractures of the tunica albuginea due to Peyronie’s disease with temporalis fascia free grafts. J Urol. 1991;145:772–6.PubMed

96.

Shioshvili TJ, Kakonashvili AP. The surgical treatment of Peyronie’s disease: replacement of plaque by free autograft of buccal mucosa. Eur Urol. 2005;48:129–33.PubMedCrossRef

97.

Cormio L, Zucchi A, Lorusso F, Selvaggio O, Figretti F, Porena M, et al. Surgical treatment of Peyronie’s disease by plaque incision and grafting with buccal mucosa. Eur Urol. 2009;55:146975.

98.

Dublin N, Stewart LH. Oral complications after buccal mucosal graft harvest for urethroplasty. BJU Int. 2004;94:867–9.PubMedCrossRef

99.

Hsu YS, Huang WJ, Kuo JY, Chung HJ, Chen KK, Chang LS. Experience of surgical treatment of Peyronie’s disease with deep dorsal venous patch in Taiwanese men. J Chin Med Assoc. 2003;66:487–91.PubMed

100.

Brock G, Kadioglu A, Lue TF. Peyronie’s disease: a modified treatment. Urology. 1993;42:300–4.PubMedCrossRef

101.

El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie’s disease. Part II: outcome analysis. J Urol. 1998;160:2050–3.PubMedCrossRef

102.

Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie’s disease. BJU Int. 2005;95:1029–33.PubMedCrossRef

103.

Radopoulos D, Vakalopoulos I, Thanos P. Preputial graft in penile curvature correction: preliminary results. Int J Impot Res. 2009;21:82–7.PubMedCrossRef

104.

Wild RM, Devine CJ, Horton CE. Dermal graft repair of Peyronie’s disease: survey of 50 patients. J Urol. 1979;121:47–50.PubMed

105.

Goyal NK, Kumar A, Das SK, Pandey AK, Sharma GK, Trivedi S, et al. Experience with plaque excision and dermal grafting in the surgical treatment of Peyronie’s disease. Singapore Med J. 2008;49:805–8.PubMed

106.

Krishnamurti S. Penile dermal flap for defect reconstruction in Peyronie’s disease: operative technique and four years’ experience in 17 patients. Int J Impot Res. 1995;7:195–208.PubMed

107.

Teloken C, Grazziotin T, Rhoden E, Da Ros C, Fornari A, Soares FC, et al. Penile straightening with crural graft of the corpus cavernosum. J Urol. 2000;164:107–8.PubMedCrossRef

108.

Schwarzer JU, Mühlen B, Schukai O. Penile corporoplasty using tunica albuginea free graft from proximal corpus cavernosum: a new technique for treatment of penile curvature in Peyronie’s disease. Eur Urol. 2003;44(6):720–3.PubMedCrossRef

109.

Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Ioannidis E. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol. 2002;167:1367–70.PubMedCrossRef

110.

O’Donnell PD. Results of surgical management of Peyronie’s disease. J Urol. 1992;148:1184–7.PubMed

111.

Kargi E, Yesilli C, Hosnuter M, Akduman B, Babuccu O, Mungan A. Relaxation incision and fascia lata grafting in the surgical correction of penile curvature in Peyronie’s disease. Plast Reconstr Surg. 2004;113:254–9.PubMedCrossRef

112.

Craatz S, Spanel-Boroeki K, Begemann JF, Olianas R, Fisch M, Hohenfellner R. The dorsal lamina of rectus sheath. a suitable grafting material for the penile tunica albuginea in Peyronie’s disease? BJU Int. 2006;97:134–7.PubMedCrossRef

113.

Chang JA, Gholami SS, Lue TF. Saphenous vein grafts. Int J Impot Res. 2002;14:375–8.PubMedCrossRef

114.

Adeniyi AA, Goorney SR, Pryor JP, Ralph DJ. The Lue procedure: an analysis of the outcome in Peyronie’s disease. BJU Int. 2002;89:404–8.PubMedCrossRef

115.

Akkus E, Ozkara H, Alici B, Demirkesen O, Akaydin A, Hattat H, et al. Incision and venous patch graft in the surgical treatment of penile curvature in Peyronie’s disease. Eur Urol. 2001;40:531–6.PubMedCrossRef

116.

De Stefani S, Savoca G, Ciampalini S, Gattuccio I, Scieri F, Belgrano E. Saphenous vein harvesting by ‘stripping’ technique and ‘W’-shaped patch covering after plaque incision in the treatment of Peyronie’s disease. Int J Impot Res. 2000;12:299–301.PubMedCrossRef

117.

Montorsi, F. et al. Five year follow-up of plaque incision and vein grafting for Peyronie’s disease [abstract 123]. Eur Urol. 2004;Suppl 3: 33.

118.

Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie’s disease surgery: a comprehensive review. J Sex Med. 2007;4:581–95.PubMedCrossRef

119.

Brannigan RE, Kim ED, Oyasu R, McVary KT. Comparison of tunica albuginea substitute for the treatment of Peyronie’s disease. J Urol. 1998;159:1064–8.PubMedCrossRef

120.

Taylor FL, Levine LA. Surgical correction of Peyronie’s disease using Tunica albuginea plication or partial plaque excision with pericardial graft: long-term followup. J Sex Med. 2008;5:2221–8.PubMedCrossRef

121.

Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie’s disease. J Urol. 2003;170:2359–62.PubMedCrossRef

122.

Chun JL, McGregor A, Krishnan R, Carson CC. A comparison of dermal and cadaveric pericardial grafts in the modified Horton-Devine procedure for Peyronie’s disease. J Urol. 2001;166:185–8.PubMedCrossRef

123.

Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJ. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie’s disease. Urology. 2003;62:105–9.PubMedCrossRef

124.

Edygio PH, Lucon AM, Arap S. Treatment of Peyronie’s disease by incomplete circumferential incision of the tunica albuginea and plaque with bovine pericardium graft. Urology. 2002;59:570–4.CrossRef

125.

Breyer BN, Brant WO, Garcia MM, Bella AJ, Lue TF. Complications of porcine small intestine submucosa graft for Peyronie’s disease. J Urol. 2007;177:589–91.PubMedCrossRef

126.

Knoll LD. Use of small intestinal submucosa graft for the surgical management of Peyronie’s disease. J Urol. 2007;178:2474–8.PubMedCrossRef

127.

Lee EW, Shindel AW, Brandes SB. Small intestinal submucosa for patch grafting after plaque incision in the treatment of Peyronie’s disease. Int Braz J Urol. 2008;34:191–6.PubMedCrossRef

128.

Kalsi JS, Christopher N, Ralph DJ, Minhas S. Plaque incision and fascia lata grafting in the surgical management of Peyronie’s disease. BJU Int. 2006;98:110–4.PubMedCrossRef

129.

Sampaio JS, Fonseca J, Passarinho A, Cristino J, Mendes J. Peyronie’s disease: surgical correction of 40 patients with relaxing incision and duramater graft. Eur Urol. 2002;41:551–5.PubMedCrossRef

130.

Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial and small intestinal submucosal grafting for Peyronie’s disease. J Sex Med. 2007;4:1500–8.PubMedCrossRef

131.

Montorsi F, Guazzoni G, Bergamaschi F, Rigatti P. Patient-partner satisfaction with semirigid penile prostheses for Peyronie’s disease: a 5‑year followup study. J Urol. 1993;150:1819–21.PubMed

132.

Wilson SK, Delk JR. A new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121–3.PubMed

133.

Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie’s disease. Int J Impot Res. 2000;12:147–51.PubMedCrossRef

134.

Carson CC. Penile prothesis implantation in the treatment of Peyronie’s disease and erectile dysfunction. Int J Impot Res. 2000;12 Suppl 4:S122–6.PubMedCrossRef

135.

Chaudhary M, Sheikh N, Asterling S, Ahmad I, Greene D. Peyronie’s disease with erectile dysfunction: penile modeling over inflatable penile prostheses. Urology. 2005;65:760–4.PubMedCrossRef

136.

Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie’s disease and drug-resistant erectile dysfunction: a single-center study. J Sex Med. 2010;7:3775–83.PubMedCrossRef

137.

Rahman NU, Carrion RE, Bochinski D, Lue TF. Combined penile placation surgery and insertion of penile prosthesis for severe penile curvature and erectile dysfunction. J Urol. 2004;171:2346–9.PubMedCrossRef

Title: Treatment of Peyronie’s Disease: 2012 Update
Authors: Ege Can Serefoglu
Wayne J. G. Hellstrom
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Urology Reports / Issue 6/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-011-0212-2

At a glance: The STEP trials

Springer Medicine

Treatment of Peyronie’s Disease: 2012 Update

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Bladder Dysfunction in Patients with Diabetes

Bladder Dysfunction and Parkinsonism: Current Pathophysiological Understanding and Management Strategies

Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction

The Scientific Rationale for Using Biomaterials in Stress Urinary Incontinence and Pelvic Organ Prolapse

Androgens are Fundamental in the Maintenance of Male Sexual Health

Updates in the Management of the Overactive Bladder in Patients with Myelomeningocele